Rising Adoption of Viscosupplementation Agents is Driving the North American Osteoarthritis Therapeutics Market

North American osteoarthritis therapeutics market is estimated to grow at a CAGR of 8.1% during the forecast period. The rising adoption of viscosupplementation agents is one of the key factors accelerating market growth. Viscosupplementation agents have been gaining significance in the region owing to the rising incidences of knee osteoarthritis. Knee osteoarthritis is one of the major causes of disability in the US. The condition develops slowly, and pain worsens with time. The rising trend towards non-surgical alternatives is a crucial factor that is driving the demand for viscosupplementation agents. It is a non-surgical medical procedure in which a hyaluronic acid (HA) is injected into a person's knee. 

Browse the full report description North American Osteoarthritis Therapeutics Market Size, Share & Trends Analysis Report, By Anatomy (Knee, Ankle, Hip, Hand, and Spine), By Drug Type (NSAIDs, Viscosupplementation Agents, Corticosteroids, and Analgesics) and Forecast, 2020-2026 at https://www.omrglobal.com/industry-reports/north-american-osteoarthritis-therapeutics-market

Viscosupplements, including Euflexxa, Orthovisc, Hyal-gan, and Synvisc, are injections that are approved by the FDA for osteoarthritis joint pain treatment. The US FDA approvals for viscosupplementation agents are offering an opportunity for the rising adoption of Viscosupplementation agents. For instance, in December 2019, Fidia Farmaceutici S.p.A., launched TRILURON (sodium hyaluronate) in the US. It is an HA-based intra-articular viscosupplement designed for pain treatment of knee osteoarthritis in patients who failed to respond sufficiently to simple analgesics (including acetaminophen) and conservative non-pharmacologic therapy.

Scope of the North American Osteoarthritis Therapeutics Market

Market Coverage

• Market number available for 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Anatomy and Drug Type
• Countries Covered- US and Canada
• Competitive Landscape- Pfizer Inc., Bayer AG, Zimmer Biomet Holdings, Inc., Sanofi S.A., and GlaxoSmithKline plc

Recent Strategic Initiatives in the North American Osteoarthritis Therapeutics Market

• In February 2020, GlaxoSmithKline plc declared the US FDA approval of Voltaren Arthritis Pain (diclofenac sodium topical gel, 1% (NSAID). It is an arthritis pain relief available as an OTC product to temporarily provide relief from arthritis pain in the knee, elbow, hand, ankle, wrist, or foot, in adults (18 years and older).  The approval of the US FDA has made it the first and only prescription-strength, NSAID topical gel for arthritis pain available OTC in the US. This approval will offer approximately 30 million Americans suffering from osteoarthritis OTC access to the topical treatment option.
• In January 2019, OrthogenRx, Inc. declared the introduction of TriVisc (sodium hyaluronate) to treat patients with osteoarthritic knee pain who have failed to get sufficient relief from physical therapy or exercise or simple painkillers. TriVisc is a highly purified HA (sodium hyaluronate; HA) solution and supports supplement the viscous properties of the fluid in the knee joint. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment dominates the market in the base year?
• Which segment will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from the pre-COVID-19 forecast

o Most affected segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

North American Osteoarthritis Therapeutics Market-Segmentation

By Anatomy

• Knee
• Ankle
• Hip
• Hand
• Spine

By Drug Type

• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Viscosupplementation Agents 
• Corticosteroids
• Analgesics

North American Osteoarthritis Therapeutics Market– Segment by Country 

• US
• Canada